Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Pneumovax 23TM in Adults Aged 50 Years and Older

Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Pneumovax 23TM in Adults Aged 50 Years and Older

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs GSK 1437173A (Primary) ; Pneumococcal vaccine
  • Indications Pneumococcal infections; Varicella zoster virus infections
  • Focus Pharmacodynamics; Registrational
  • Acronyms ZOSTER-035
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 28 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 11 Jul 2016 This trial was completed in Estonia (end date: 17-06-2016), according to European Clinical Trials Database.
    • 18 Jan 2015 Planned End Date changed from 1 Nov 2015 to 1 Jul 2016 as reported by ClinivalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top